No Data
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 price target.
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript